Soberana 02 (English Wikipedia)

"Argentina comenzó a negociar con Cuba la vacuna Soberana" [Argentina began negotiating the Soberana vaccine with Cuba]. Cadena 3 Argentina (in Spanish). Retrieved 7 May 2021.

cadenagramonte.cu

"Intervention study with Covid-19 vaccine candidate Abdala begins". Radio Cadena Agramonte. Archived from the original on 28 April 2021. Retrieved 28 April 2021.

caribbeannationalweekly.com

"Cuba's COVID-19 Vaccines Being Sought After by CARICOM Countries". Caribbean News. 9 April 2021. Retrieved 7 May 2021.

cecmed.cu

"Aprueba el CECMED la Autorización de Uso en Emergencia a la Vacuna cubana SOBERANA® 02 en población pediátrica | CECMED". www.cecmed.cu (in Spanish). Retrieved 9 September 2021.

cnbc.com

Meredith S (23 February 2021). "'Sun, sea, sand and Soberana 02': Cuba open to inoculating tourists with homegrown Covid vaccine". CNBC.

dire.it

"Vaccino, Cuba pronta a produrre 100 milioni di dosi di 'Soberana 02'". Dire (in Italian). 21 January 2021.

doi.org

Mallapaty S (August 2021). "Iran hopes to defeat COVID with home-grown crop of vaccines". Nature. 596 (7873): 475. Bibcode:2021Natur.596..475M. doi:10.1038/d41586-021-02216-z. PMID 34404947. S2CID 237198729.
Gorry C (October 2020). "SOBERANA, Cuba's COVID-19 Vaccine Candidates: Dagmar García-Rivera PhD". MEDICC Review. 22 (4): 10–15. doi:10.37757/mr2020.v22.n4.11. PMID 33295312. S2CID 228079254.
Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. PMID 34637324. S2CID 238747462.
Malik JA, Mulla AH, Farooqi T, Pottoo FH, Anwar S, Rengasamy KR (May 2021). "Targets and strategies for vaccine development against SARS-CoV-2". Biomedicine & Pharmacotherapy. 137: 111254. doi:10.1016/j.biopha.2021.111254. PMC 7843096. PMID 33550049.
Mostafavi E, Eybpoosh S, Karamouzian M, Khalili M, Haji-Maghsoudi S, Salehi-Vaziri M, et al. (May 2023). "Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial". JAMA Network Open. 6 (5). JAMA network: e2310302. doi:10.1001/jamanetworkopen.2023.10302. PMC 10157429. PMID 37133864. S2CID 258461748.
Santos IC (January 2021). "Rapid response to: Covid 19: Hope is being eclipsed by deep frustration". BMJ. 372: n171. doi:10.1136/bmj.n171.
Valdes-Balbin Y, Santana-Mederos D, Quintero L, Fernández S, Rodriguez L, Sanchez Ramirez B, et al. (July 2021). "SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies". ACS Chemical Biology. 16 (7): 1223–1233. doi:10.1021/acschembio.1c00272. PMID 34219448. S2CID 235734990.
Mega ER (April 2021). "Can Cuba beat COVID with its homegrown vaccines?". Nature. doi:10.1038/d41586-021-01126-4. PMID 33927405. S2CID 233458503.

dw.com

"Coronavirus: Vacuna cubana Soberana 02 alista fase 3 y ensayos". Deutsche Welle (in Spanish). 5 February 2021.
"Coronavirus: Vacuna cubana Soberana 02 alista fase 3 y ensayos". Deutsche Welle (in Spanish). 5 February 2021. Las expectativas sobre Soberana 02 son tales que el titular del organismo estatal que desarrolló la vacuna, Vicente Vérez, confirmó que mientras se aguarden los resultados de la Fase 3 solo en La Habana, en abril se dará inicio a la producción del primer lote, de alrededor de 100 mil dosis.

facebook.com

"[Translated]In more than 62 thousand applied doses of #Soberana02 the safety of the vaccine has been demonstrated. Adverse effects have been: 👉 Pain at the injection site (20%). 👉 Redness at the injection site (5%). 👉 Feeling of general malaise (5%)". Facebook. Retrieved 7 May 2021.

fdaghana.gov.gh

"CEO of FDA Discusses Production of Covid-19 Vaccine With Cuban Ambassador". www.fdaghana.gov.gh. Retrieved 5 May 2021.

finlay.edu.cu

"Autorizo de emergencia SOBERANA 02 en Irán". finlay.edu.cu. Instituto Finlay de Vacunas. 1 July 2021. Retrieved 6 July 2021.

france24.com

"Cuba apuesta por crear primera vacuna de América Latina contra el covid-19". France 24 (in Spanish). 21 January 2021. Retrieved 24 January 2021.

gmanetwork.com

"Cuba grants emergency approval to second homegrown COVID-19 vaccine". GMA News. 21 August 2021.

gnbcc.net

"Cuba To Transfer COVID-19 Vaccine Technology To Ghana". www.gnbcc.net. Retrieved 5 May 2021.

harvard.edu

ui.adsabs.harvard.edu

Mallapaty S (August 2021). "Iran hopes to defeat COVID with home-grown crop of vaccines". Nature. 596 (7873): 475. Bibcode:2021Natur.596..475M. doi:10.1038/d41586-021-02216-z. PMID 34404947. S2CID 237198729.

ilfoglio.it

"L'esempio cubano sui vaccini". www.ilfoglio.it (in Italian). Retrieved 7 May 2021.

infobae.com

"Sin definiciones sobre cuándo podrían llegar, el Gobierno avanza para conseguir las vacunas Soberana y Abdala de Cuba". infobae (in European Spanish). 7 May 2021. Retrieved 7 May 2021.

irct.ir

en.irct.ir

"IRCT | Efficacy, safety, and immunogenicity of Soberana recombinant vaccine (product of Finlay Institute) based on RBD protein subunit of Sars-Cov-2 in a 2-dose regimen with and without a booster dose: a double-blind, randomized, placebo-controlled phase III clinical trial in the Iranian population of 18-80 years". en.irct.ir. Archived from the original on 7 September 2021. Retrieved 7 September 2021.

irna.ir

طاهره نبی الهی قهفرخی (21 November 2021). "نتایج مطالعات ۶ واکسن ایرانی کرونا ارایه شد". ایرنا (in Persian). Retrieved 23 November 2021.
جبارپور, عبدالکریم (2 December 2021). "پاستوکووک ۹۶.۵ درصد از بستری و ابتلای شدید به کرونا پیشگیری می‌کند". IRNA (in Persian). Retrieved 9 December 2021.

isna.ir

"کاهش حدود ۶۰ درصدی اثربخشی "فایزر" مقابل "دلتا" / جزییات ایمنی‌زایی واکسن "پاستوکووک"" [About 60% reduction in Pfizer efficacy against Delta / Immunogenicity details of Pastococcus vaccine]. ایسنا (in Persian). 9 October 2021. Retrieved 2 November 2021.
"توضیحاتی درباره اثربخشی واکسن پاستوکووک/ عوارض پس از تزریق پاستوکووک". ایسنا (in Persian). 21 November 2021. Retrieved 23 November 2021.
"تولید ۸ میلیون دز واکسن "پاستوکووک"؛ تاکنون / زمان تزریق دز سوم این واکسن". ایسنا (in Persian). 27 November 2021. Retrieved 27 November 2021.

jornada.com.mx

"Cuba anuncia fase 3 de la vacuna Soberana 02". La Jornada (in Spanish). 7 February 2021. Una vez que superen las etapas clínicas, la OMS podría contar con el fármaco cubano, afirmó Moya, y "pasar a ser parte del grupo de vacunas que se oferten a través del Fondo Rotatorio", un mecanismo que desde hace cuatro décadas permite gestionar antígenos e insumos a los países de las Américas.

lse.ac.uk

blogs.lse.ac.uk

Yaffe H (31 March 2021). "Cuba's five COVID-19 vaccines: the full story on Soberana 01/02/Plus, Abdala, and Mambisa". LSE Latin America and Caribbean blog. Retrieved 31 March 2021.

medicalxpress.com

"Cuba begins testing 2nd COVID-19 vaccine on health care workers". medicalxpress.com. Retrieved 11 April 2021.

medrxiv.org

Toledo-Romani ME (6 November 2021). "Efficacy and safety of SOBERANA 02, a COVID-19 conjugate vaccine in heterologous three-dose combination". medRxiv 10.1101/2021.10.31.21265703v2.

nbcnews.com

"Cuba says it's 'betting it safe' with its own Covid vaccine". NBC News. 10 April 2021. Retrieved 11 April 2021.

news.cn

english.news.cn

"Cuba reports lower numbers of COVID-19 cases, deaths" Xinhua. Retrieved April 17 2022.

nih.gov

pubmed.ncbi.nlm.nih.gov

Mallapaty S (August 2021). "Iran hopes to defeat COVID with home-grown crop of vaccines". Nature. 596 (7873): 475. Bibcode:2021Natur.596..475M. doi:10.1038/d41586-021-02216-z. PMID 34404947. S2CID 237198729.
Gorry C (October 2020). "SOBERANA, Cuba's COVID-19 Vaccine Candidates: Dagmar García-Rivera PhD". MEDICC Review. 22 (4): 10–15. doi:10.37757/mr2020.v22.n4.11. PMID 33295312. S2CID 228079254.
Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. PMID 34637324. S2CID 238747462.
Malik JA, Mulla AH, Farooqi T, Pottoo FH, Anwar S, Rengasamy KR (May 2021). "Targets and strategies for vaccine development against SARS-CoV-2". Biomedicine & Pharmacotherapy. 137: 111254. doi:10.1016/j.biopha.2021.111254. PMC 7843096. PMID 33550049.
Mostafavi E, Eybpoosh S, Karamouzian M, Khalili M, Haji-Maghsoudi S, Salehi-Vaziri M, et al. (May 2023). "Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial". JAMA Network Open. 6 (5). JAMA network: e2310302. doi:10.1001/jamanetworkopen.2023.10302. PMC 10157429. PMID 37133864. S2CID 258461748.
Valdes-Balbin Y, Santana-Mederos D, Quintero L, Fernández S, Rodriguez L, Sanchez Ramirez B, et al. (July 2021). "SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies". ACS Chemical Biology. 16 (7): 1223–1233. doi:10.1021/acschembio.1c00272. PMID 34219448. S2CID 235734990.
Mega ER (April 2021). "Can Cuba beat COVID with its homegrown vaccines?". Nature. doi:10.1038/d41586-021-01126-4. PMID 33927405. S2CID 233458503.

ncbi.nlm.nih.gov

Malik JA, Mulla AH, Farooqi T, Pottoo FH, Anwar S, Rengasamy KR (May 2021). "Targets and strategies for vaccine development against SARS-CoV-2". Biomedicine & Pharmacotherapy. 137: 111254. doi:10.1016/j.biopha.2021.111254. PMC 7843096. PMID 33550049.
Mostafavi E, Eybpoosh S, Karamouzian M, Khalili M, Haji-Maghsoudi S, Salehi-Vaziri M, et al. (May 2023). "Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial". JAMA Network Open. 6 (5). JAMA network: e2310302. doi:10.1001/jamanetworkopen.2023.10302. PMC 10157429. PMID 37133864. S2CID 258461748.

nodal.am

"Cuba espera fabricar 100 millones de dosis de su candidato vacunal Soberana 02". Nodal (in Spanish). 21 January 2021.

nytimes.com

Augustin E (12 May 2021). "Cuba deploys unproven homegrown vaccines, hoping to slow an exploding virus outbreak". The New York Times. ISSN 0362-4331. Retrieved 14 May 2021.

oncubanews.com

"Coronavirus: Cuba will produce 100 million doses of its Soberana 02 vaccine". OnCubaNews English. 21 January 2021. Retrieved 7 May 2021.
"Cuba negotiates with other countries to develop phase 3 of Soberana 02 vaccine". OnCubaNews English. 30 December 2020. Retrieved 24 January 2021.
"Cuba sends 100,000 doses of the Soberana 02 vaccine candidate to Iran" oncubanews.com. Retrieved 19 March 2021.

pagina12.com.ar

"Soberana 02: Cuba prepara cien millones de dosis de la vacuna contra el coronavirus | "No somos una multinacional. Nuestro fin es crear salud", dijo el director del Instituto Finlay de Vacunas" [Soberana 02: Cuba prepares one hundred million doses of the coronavirus vaccine | "We are not a multinational. Our goal is to create health," said the director of the Finlay Vaccine Institute]. PAGINA12 (in Spanish). 22 January 2021. Retrieved 7 May 2021.

pasteurcovac.ir

"PasteurCovac". Pasteur Institute of Iran. Archived from the original on 17 January 2022. Retrieved 31 January 2022.

plenglish.com

"Cuban scientists, health workers received first anti-Covid-19 dose". www.plenglish.com/index.php?o=rn&id=66247&SEO=cuban-scientists-health-workers-received-first-anti-covid-19-dose (in European Spanish). Retrieved 11 April 2021.
"Diaz-Canel underscores success of Covid-19 vaccination among children". Prensa Latina. Retrieved 17 April 2022.
"Cuba administers over 62,000 doses in intervention trials". Prensa Latina (in European Spanish). Retrieved 28 April 2021.

poresto.net

"América Latina apura una vacuna propia. Cuba, adelante; México avanza. Pero no son los únicos". www.poresto.net (in Spanish). Retrieved 28 April 2021.

pressenza.com

"Cuban Vaccine Ready in July. Interview with the Cuban Ambassador to the Czech Republic". Pressenza. 23 March 2021. Retrieved 29 April 2021.

radiocut.fm

"Ilarregui (Embajador en Cuba): "Durante Este Año Podremos Tener Vacunas Cubanas en Argentina"" [Ilarregui (Ambassador to Cuba): "During this year we will be able to have Cuban vaccines in Argentina"]. RadioCut (in Spanish). Retrieved 7 May 2021.

reuters.com

Marsh S (9 January 2021). "Cuba to collaborate with Iran on coronavirus vaccine". Reuters. Retrieved 24 January 2021.
Marsh S (24 March 2021). "Nearly all Havana (sic) to receive experimental Cuban COVID-19 vaccines". Reuters. Retrieved 28 April 2021.

riotimesonline.com

"Cuban government offers to transfer COVID-19 Soberana 02 vaccine technology to Ghana". Rio Times Online. 16 February 2021.

semanticscholar.org

api.semanticscholar.org

Mallapaty S (August 2021). "Iran hopes to defeat COVID with home-grown crop of vaccines". Nature. 596 (7873): 475. Bibcode:2021Natur.596..475M. doi:10.1038/d41586-021-02216-z. PMID 34404947. S2CID 237198729.
Gorry C (October 2020). "SOBERANA, Cuba's COVID-19 Vaccine Candidates: Dagmar García-Rivera PhD". MEDICC Review. 22 (4): 10–15. doi:10.37757/mr2020.v22.n4.11. PMID 33295312. S2CID 228079254.
Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. PMID 34637324. S2CID 238747462.
Mostafavi E, Eybpoosh S, Karamouzian M, Khalili M, Haji-Maghsoudi S, Salehi-Vaziri M, et al. (May 2023). "Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial". JAMA Network Open. 6 (5). JAMA network: e2310302. doi:10.1001/jamanetworkopen.2023.10302. PMC 10157429. PMID 37133864. S2CID 258461748.
Valdes-Balbin Y, Santana-Mederos D, Quintero L, Fernández S, Rodriguez L, Sanchez Ramirez B, et al. (July 2021). "SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies". ACS Chemical Biology. 16 (7): 1223–1233. doi:10.1021/acschembio.1c00272. PMID 34219448. S2CID 235734990.
Mega ER (April 2021). "Can Cuba beat COVID with its homegrown vaccines?". Nature. doi:10.1038/d41586-021-01126-4. PMID 33927405. S2CID 233458503.

sld.cu

rpcec.sld.cu

"SOBERANA 02-FaseIII". Retrieved 9 September 2021.
"SOBERANA – INTERVENTION | Registro Público Cubano de Ensayos Clínicos". rpcec.sld.cu. Retrieved 11 April 2021.
"SOBERANA 02 | Registro Público Cubano de Ensayos Clínicos". Cuban Registry of Clinical Trials (in Spanish). Retrieved 24 January 2021.
"SOBERANA PEDIATRIA". Cuban Registry of Clinical Trials. Retrieved 12 August 2021.
"SOBERANA PEDIATRIA CLINICA 1". Cuban Registry of Clinical Trials. Retrieved 12 August 2021.

tasnimnews.com

"اثربخشی واکسن پاستور در پیشگیری از بستری کرونایی ۹۲ درصد است + جزئیات" [Pasteur vaccine is 92% effective in preventing coronary hospitalization + details]. خبرگزاری تسنیم | Tasnim News Agency (in Persian). 9 October 2021. Retrieved 2 November 2021.